New treatment for common retinal diseases shows promise
For the past decade and a half, eye doctors have been treating these conditions with drugs that block a protein, VEGF, that's responsible for spurring new vessel growth.
New York: Researchers have uncovered a potential new strategy for treating eye diseases that affect millions of people around the world, often resulting in blindness.
Many serious eye diseases — including age-related macular degeneration, diabetic retinopathy and related disorders of the retina — feature abnormal overgrowth of new retinal blood vessel branches, which can lead to progressive loss of vision.
It’s a phenomenon called “neovascularisation.”
For the past decade and a half, eye doctors have been treating these conditions with drugs that block a protein, VEGF, that’s responsible for spurring new vessel growth.
Such drugs have improved the treatment of these conditions, but don’t always work well and have potential safety issues.
The current study, published in the journal Proceedings of the National Academy of Sciences, showed that a new approach that doesn’t target VEGF directly is highly effective in mice and has broader benefits than a standard VEGF-blocking treatment.
“We were thrilled to see how well this worked in the animal model,” said study author Rebecca Berlow from Scripps Research Institute in the US.
“There really is a need for another way to treat patients who do not respond well to anti-VEGF treatments,” Berlow added.
For the findings, the research team conducted tests in a mouse model of retinal hypoxia and neovascularisation, using a fragment of CITED2 that contains its functional, hypoxic-response-blocking elements.
They showed that when a solution of the CITED2 fragment was injected into the eye, it lowered the activity of genes that are normally switched on by HIF-1a in retinal cells, and significantly reduced neovascularisation.
Moreover, it did so while preserving, or allowing to re-grow, the healthy capillaries in the retina that would otherwise have been destroyed –researchers call it “vaso-obliteration” — in this model of retinal disease.
In the same mouse model, the researchers tested a drug called aflibercept, a standard anti-VEGF treatment.
It helped reduce neovascularisation, but did not prevent the destruction of retinal capillaries.
However, reducing the dose of aflibercept and combining it with the CITED2 fragment yielded better results than either alone, strongly reducing neovascularisation while preserving and restoring retinal capillaries.
CITED2’s ability to combine these two benefits appears to represent a key advance, the researchers concluded.
The researchers now hope to develop the CITED2-based treatment further, with the ultimate goal of testing it in human clinical trials.
